Published in
Elsevier, Lung Cancer, (170), p. 11-19, 2022
DOI: 10.1016/j.lungcan.2022.06.002
Links
Tools
Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 